218
Participants
Start Date
September 28, 2023
Primary Completion Date
December 30, 2026
Study Completion Date
December 30, 2027
ABO2011 Injection
Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection
Toripalimab
Anti-PD-1 antibody
RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
RECRUITING
Shanxi Cancer hospital, Shanxi
RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Abogen Biosciences (Shanghai) Co., Ltd
INDUSTRY
Suzhou Abogen Biosciences Co., Ltd.
INDUSTRY